← Back to Screener
Akebia Therapeutics, Inc. (AKBA)
Price$1.02
Value ScoreB
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-49.70%
Price vs S&P 500 (4W)-32.11%
VGM Score42.89
Market Capitalization$272.28M
All Metrics
P/CF (Annual)4.00x
Book Value / Share (Quarterly)$0.10
P/TBV (Annual)3.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-6.88%
Cash Flow / Share (Quarterly)$0.20
Price vs S&P 500 (YTD)-47.58%
Gross Margin (TTM)79.25%
Net Profit Margin (TTM)-8.83%
EPS (TTM)$-0.08
10-Day Avg Trading Volume6.50M
EPS Excl Extra (TTM)$-0.08
Revenue Growth (5Y)-4.32%
EPS (Annual)$-0.02
ROI (Annual)-2.36%
Gross Margin (Annual)82.91%
Net Profit Margin (5Y Avg)-47.54%
Cash / Share (Quarterly)$0.61
Revenue Growth QoQ (YoY)-6.61%
ROA (Last FY)-1.42%
Revenue Growth TTM (YoY)25.69%
EBITD / Share (TTM)$0.02
ROE (5Y Avg)-487.05%
Operating Margin (TTM)2.28%
Cash Flow / Share (Annual)$0.23
P/B Ratio9.95x
P/B Ratio (Quarterly)13.60x
Net Income / Employee (Annual)$-27,600
EV / Revenue (TTM)1.31x
Net Interest Coverage (TTM)0.85x
ROA (TTM)-5.66%
EV / EBITDA (TTM)54.06x
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)1.30x
3-Month Avg Trading Volume3.53M
52-Week Price Return-66.11%
EV / Free Cash Flow (Annual)5.07x
Revenue / Employee (TTM)$1,198,000
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)1.15x
Asset Turnover (Annual)0.63x
52-Week High$4.08
Operating Margin (5Y Avg)-39.76%
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)90.83%
26-Week Price Return-33.77%
Quick Ratio (Annual)1.42x
13-Week Price Return-22.73%
Total Debt / Equity (Annual)5.94x
Current Ratio (Quarterly)1.40x
Enterprise Value$303.63M
Revenue / Share Growth (5Y)-15.46%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)-53.14%
Revenue / Employee (Annual)$1,217,500
Inventory Turnover (Annual)2.53x
Pretax Margin (Annual)-1.58%
Cash / Share (Annual)$0.70
3-Month Return Std Dev78.03%
Gross Margin (5Y Avg)77.94%
Net Income / Employee (TTM)$-105,700
ROE (Last FY)-16.39%
Net Interest Coverage (Annual)0.11x
EPS Basic Excl Extra (Annual)$-0.02
P/FCF (TTM)3.70x
Receivables Turnover (TTM)3.75x
EV / Free Cash Flow (TTM)5.81x
Total Debt / Equity (Quarterly)7.09x
EPS Incl Extra (TTM)$-0.08
Receivables Turnover (Annual)5.80x
ROI (TTM)-9.14%
P/S Ratio (TTM)1.17x
Pretax Margin (5Y Avg)-47.40%
Revenue / Share (Annual)$0.92
Tangible BV / Share (Annual)$0.70
Forward P/E380.50x
Price vs S&P 500 (52W)-94.32%
Year-to-Date Return-36.65%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-26.82%
Net Profit Margin (Annual)-2.26%
Month-to-Date Return-26.09%
Cash Flow / Share (TTM)$-0.13
EBITD / Share (Annual)$0.09
Operating Margin (Annual)9.95%
LT Debt / Equity (Annual)5.40x
P/CF (TTM)4.51x
ROI (5Y Avg)-94.04%
LT Debt / Equity (Quarterly)5.77x
EPS Basic Excl Extra (TTM)$-0.08
P/TBV (Quarterly)25.01x
P/B Ratio (Annual)13.10x
Inventory Turnover (TTM)2.95x
Pretax Margin (TTM)-8.07%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)-32.47%
Beta0.27x
P/FCF (Annual)4.55x
Revenue / Share (TTM)$0.87
ROE (TTM)-62.72%
52-Week Low$0.88
vGradeB
gGradeC
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.03est. -0.03
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.36
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AKBAAkebia Therapeutics, Inc. | B | C | D | $1.02 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Akebia Therapeutics is a biopharmaceutical company specializing in chronic kidney disease treatments. Its marketed products include Auryxia for serum phosphorus control and iron deficiency anemia in CKD patients in the US, and Vafseo for CKD-related anemia in Japan. The company is advancing HIF-PH inhibitors in preclinical development.